Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuitive Surgical
ISRG
|
+$828M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$788M |
| 3 |
Qualcomm
QCOM
|
+$771M |
| 4 |
Apple
AAPL
|
+$719M |
| 5 |
Baxter International
BAX
|
+$571M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.57B |
| 2 |
Wells Fargo
WFC
|
+$967M |
| 3 |
KKR & Co
KKR
|
+$455M |
| 4 |
Booking.com
BKNG
|
+$401M |
| 5 |
GGP
GGP Inc.
GGP
|
+$384M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 29.32% |
| 2 | Technology | 13.38% |
| 3 | Healthcare | 9.68% |
| 4 | Financials | 9.31% |
| 5 | Consumer Discretionary | 8.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
VanEck Semiconductor ETF
SMH
$71.9B
| $578M | 0.14% |
10,868,438
-2,351,248
| -18% | -$125M |
2013 Q2
21 quarters
|
|
152
SPDR Gold Trust
GLD
$141B
| $569M | 0.14% |
5,049,473
+297,192
| +6% | +$34.1M |
2013 Q2
21 quarters
|
|
153
State Street Industrial Select Sector SPDR ETF
XLI
$31B
| $569M | 0.14% |
7,251,781
-3,262,704
| -31% | -$249M |
2013 Q2
21 quarters
|
|
154
Enterprise Products Partners
EPD
$77.6B
| $565M | 0.14% |
19,671,087
+1,472,976
| +8% | +$42.6M |
2013 Q2
21 quarters
|
|
155
Invesco S&P 500 Low Volatility ETF
SPLV
$7.09B
| $545M | 0.14% |
11,008,998
+1,698,448
| +18% | +$83.5M |
2013 Q2
21 quarters
|
|
156
Micron Technology
MU
$1.12T
| $541M | 0.14% |
11,960,907
+6,574,409
| +122% | +$332M |
2013 Q2
21 quarters
|
|
157
Marathon Petroleum
MPC
$129B
| $539M | 0.13% |
6,740,004
+941,397
| +16% | +$74.4M |
2013 Q2
21 quarters
|
|
158
Kimberly-Clark
KMB
$32.4B
| $538M | 0.13% |
4,738,469
+1,595,818
| +51% | +$179M |
2013 Q2
21 quarters
|
|
159
Vanguard FTSE All-World ex-US ETF
VEU
$67.8B
| $519M | 0.13% |
9,965,201
+663,317
| +7% | +$34.6M |
2013 Q2
21 quarters
|
|
|
RDS.B
160
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $518M | 0.13% |
7,302,123
-540,448
| -7% | -$37.4M |
2013 Q2
21 quarters
|
|
161
Sherwin-Williams
SHW
$77.9B
| $518M | 0.13% |
3,413,040
-70,491
| -2% | -$10.4M |
2013 Q2
21 quarters
|
|
162
iShares China Large-Cap ETF
FXI
$3.92B
| $513M | 0.13% |
11,983,026
+1,346,335
| +13% | +$57M |
2013 Q2
21 quarters
|
|
163
Diageo
DEO
$48.9B
| $510M | 0.13% |
3,601,655
-86,683
| -2% | -$12.4M |
2013 Q2
21 quarters
|
|
|
AGN
164
DELISTED
Allergan plc
AGN
| $507M | 0.13% |
2,660,131
+483,860
| +22% | +$88.9M |
2013 Q2
21 quarters
|
|
165
Eli Lilly
LLY
$1.05T
| $506M | 0.13% |
4,710,695
+237,158
| +5% | +$23.7M |
2013 Q2
21 quarters
|
|
166
First Trust Preferred Securities and Income ETF
FPE
$5.94B
| $494M | 0.12% |
25,855,426
+8,077
| +0% | +$155K |
2013 Q2
21 quarters
|
|
167
iShares Biotechnology ETF
IBB
$10.5B
| $491M | 0.12% |
4,026,110
+143,209
| +4% | +$16.9M |
2013 Q2
21 quarters
|
|
168
iShares 20+ Year Treasury Bond ETF
TLT
$48.4B
| $490M | 0.12% |
4,181,546
-1,303,982
| -24% | -$157M |
2013 Q2
21 quarters
|
|
169
iShares Select Dividend ETF
DVY
$22.6B
| $490M | 0.12% |
4,911,125
+271,391
| +6% | +$27.2M |
2013 Q2
21 quarters
|
|
170
Mercado Libre
MELI
$96.7B
| $488M | 0.12% |
1,433,980
-59,466
| -4% | -$20.1M |
2013 Q2
21 quarters
|
|
171
ConocoPhillips
COP
$164B
| $486M | 0.12% |
6,275,872
+1,449,736
| +30% | +$105M |
2013 Q2
21 quarters
|
|
172
Sempra
SRE
$53.3B
| $483M | 0.12% |
8,493,960
-143,592
| -2% | -$8.31M |
2013 Q2
21 quarters
|
|
173
Colgate-Palmolive
CL
$70.9B
| $483M | 0.12% |
7,212,524
+941,008
| +15% | +$62.7M |
2013 Q2
21 quarters
|
|
174
Vornado Realty Trust
VNO
$6.28B
| $477M | 0.12% |
6,530,405
-503,576
| -7% | -$37.3M |
2013 Q2
21 quarters
|
|
175
Vanguard Information Technology ETF
VGT
$155B
| $476M | 0.12% |
18,786,160
-596,880
| -3% | -$14.5M |
2013 Q2
21 quarters
|
|
Similar funds
Morgan Stanley's Q3 2018 Portfolio in Review
As of Q3 2018, Morgan Stanley held 7,051 positions worth $400B, up 7.9% from $370B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Morgan Stanley's Q3 2018 filing shows 207 new, 2,867 increased, 3,205 reduced and 166 closed positions. Its largest new stake was Elanco Animal Health: 9,012,591 shares worth $314M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.57B.
By sector, the portfolio is most concentrated in Miscellaneous at 29% of assets, down from 30% a quarter earlier, followed by Technology and Healthcare.
- Morgan Stanley's largest Q3 2018 buy was Elanco Animal Health: 9,012,591 shares worth $314M.
- Morgan Stanley added most to Intuitive Surgical in Q3 2018, an estimated $828M increase.
- Morgan Stanley's biggest Q3 2018 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.57B.
- Morgan Stanley fully exited GGP Inc. in Q3 2018, selling an estimated $384M.
- Morgan Stanley's ten largest holdings make up 15% of its $400B portfolio in Q3 2018.
- Morgan Stanley opened 207 new positions and closed 166 in Q3 2018.
- Morgan Stanley's portfolio value rose 7.9% quarter-over-quarter to $400B.
Based on Morgan Stanley's 13F filing for Q3 2018, filed 14 Nov 2018.